Biotech-Fan (@ATLanalyst) profile picture

Atlanta area investor & consultant: biotech, cryptos, title/mortgage securities. Advocate of alternatives to animal testing. Not giving investment advice.

Joined October 2010
Photo by Biotech-Fan (@ATLanalyst)Photo by Biotech-Fan (@ATLanalyst)Photo by Biotech-Fan (@ATLanalyst)Photo by Biotech-Fan (@ATLanalyst)Photo by Biotech-Fan (@ATLanalyst)Photo by Biotech-Fan (@ATLanalyst)Photo by Biotech-Fan (@ATLanalyst)Photo by Biotech-Fan (@ATLanalyst)Photo by Biotech-Fan (@ATLanalyst)Photo by Biotech-Fan (@ATLanalyst)
Biotech-Fan retweeted
Socialism vs Capitalism
729
3,565
230
23,875
1,193,132
Maybe $UNCY should have filed with their 2nd/backup CDMO they said they had since the first never got reinspected?
Replying to @LukesGood232195
How can we tak about any defficiencies, when the same facility found at fault at the previous CRL, was not inspected on the second $UNCY CRL ? Why not a 90 day review delay if FDA is at fault here ?
1
891
Coincidentally $UNCY didn't run up much into pdufa date this time. Just a coincidence, I'm sure. 🤪
You’re unable to view this Post because this account owner limits who can view their Posts. Learn more
2
860
I like to think that $VKTX has good management, but, why have they been sitting on VK2809 for NASH/MASH for almost *2 years* since reporting good Ph2 results in June 2024? Seems like total radio silence. I know it's not their top focus, but if it has value shouldn't they have monetized it?
5
15
3,963
#Silver $SLV $SIL. This call from right before Friday's crash was easier to post than to follow. Lol.
#Silver $SLV $SIL What part of this chart doesn't scream "Take profits!"
1
881
#Silver $SLV $SIL What part of this chart doesn't scream "Take profits!"
1
2
1,373
50% drop in $RVPH this morning because FDA advised them to complete 2nd ph3 trial before submitting NDA; but I see the 2nd Ph3 trial was already planned, so could this news have been that unexpected?
3
3
1,832
Found this in their 10Q which I guess explains it This
3
339
Congrats to $EXAS. At $105 /sh, that $23B EV, 7 x this years sales, and 338 x next years earnings. Seems like a rich valuation so I assume Abbott's confident in their pipeline.
1
1
1
567
#silver #gold $SLV $GLD What an amazing run precious metals have had this year. Compared to all other commodity futures. I guess it can thank government reckless spending, debt, and money printing.
2
464
Why the bidding war for $MTSR yet crickets for $VKTX? Isn't MTSR about 6 months behind VKTX? Is it hangover of disappointing oral results? But isn't IV VK2735 still best in class efficacy & safety? And VK2809 still a great MASH candidate?
1
3
738
$TGTX buying opportunity as it sells off despite a good Q just announced. Methinks sell off is due to market planning to sell on earnings as they expected TGTX to beat guidance and pop as their pattern is to beat guidance.
1
521
$CYBN PIPE @ $6.51 + .35 Warrants @ $8.14. Nice names in the deal. Up 20% to $7.80. Not sure what to make of them.
Cybin Announces $175 Million Registered Direct Offering $CYBN tinyurl.com/298hgef8
5
910
$PHRRF gets a deal done shortly after FDA approval. Specifics vague, but good to see it.
This quoted post is unavailable.
1
7
2,973
$LRMR, well at least the runup and no dip before data showed there was no leak.
5
887
$INBS 😩 New study required, delays anticipated approval by a year.
Intelligent Bio Solutions Advances Preparations and Provides Updated Timeline for Anticipated FDA 510(k) Submission and Clearance $INBS tinyurl.com/22h4npa6
596
Selling my $MTSR at $53 - it already priced in the full 1st $5 CVR milestone payout, and the others could be years away. BWDIK.
$PFE $MSTR $22.50 CVR breakdown; - $5/share following the Phase 3 trial start of MET-097i+MET-233i combination. - $7/share following FDA approval of MET-097i monotherapy. - $10.50/share following FDA approval of monthly MET-097i+MET-233i combination
There's a new version of this post
184
$REVB out with big news, according to them at least. Anyone looking into this inflammation controlling data?
Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study $REVB tinyurl.com/26a8l26z
983
$OSTX I take this confusing PR to mean we are still submitting a BLA even though FDA does not know what guidelines they will use to measure efficacy. Hmmm. "The Company continues to seek direction on which FDA guidance to rely upon with respect to clinical efficacy for the pending BLA submission"
OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 Meeting $OSTX tinyurl.com/298ud6hk
854